Measuring the return from pharmaceutical innovation 2021
Since 2010, we have been tracking the returns on R&D investment that the largest biopharma companies might expect to achieve from their late-stage pipelines. This year’s analysis shows a large improvement in the average internal rate of return on pharmaceutical innovation for our combined cohort.
The future unmasked
Predicting the future of healthcare and life sciences in 2025
What does the future hold for the life sciences and healthcare industry? Our latest predictions report looks ahead to the year 2025 to help you see what’s coming and to keep your organisation moving forward.
Securing Trust in the Global COVID-19 Supply Chain
From development and delivery to acceptance and administration
COVID-19 vaccines and therapeutics, and the associated medical devices and consumables, present an urgent need for a protected supply chain and a system of traceability built around globally identified products. Are organizations ready to take on the challenge?
2021 global life sciences outlook
Possibility is now reality, sustaining forward momentum
Navigating the pandemic has been an all-encompassing, once-in-a-lifetime challenge. Globally, life sciences companies responded with leadership and are emerging stronger. Explore how life sciences companies responded and areas where they can build resiliency going forward.
Seeds of Change
Measuring the return of pharmaceutical innovation 2020
Our latest report looks at the current state of R&D returns for 15 leading biopharma companies from May 2019 to April 2020, the impact of the pandemic on R&D pipelines during 2020 and identifies lessons that can help change the R&D paradigm towards a future with higher returns.
Covid-19: Impact and Recovery for the Life Sciences Industry
The Life Sciences industry in Ireland continues to respond to the COVID-19 pandemic, an unparalleled situation. Globally, the sector is collectively working on developing vaccines and treatments, and ramping up the production of new diagnostic devices, ventilators and pumps.
As M&A activity and divestitures continue, life sciences companies shouldn’t overlook product transfers
Imagine a $50 billion life sciences acquisition where company executives don’t properly plan for the transfer of some products. The potential result: Supply disruptions for patients and millions of dollars in unplanned inventory write-offs.
Validation using Agile in the Life Sciences and Health Care Industry
The advent of Agile Methodology has disrupted the traditional development methods with its clear focus on continuous development, agility and over all “lean” concept.
The Life Science and Health Care Industry (LSHC) has always been in the lime light for its strict regulations. The advent of Agile Methodology has disrupted the traditional development methods with its clear focus on continuous development, agility and over all “lean” concept.
The future of biopharma innovation
Biopharma’s future will be focused on developing therapies for the multiple diseases that still lack treatments and creating more precise treatment regimens that target smaller populations or individual patients. Developing these treatments brings new challenges.
Medtech and the Internet of Medical Things
How connected medical devices are transforming health care
New research from Deloitte UK Centre for Health Solutions examines how the IoMT is transforming medtech’s role in health care. It outlines how medtech companies can get digital transformation right – whether through adapting their existing business models, inventing new ones or both.
A decade of shrinking returns might be prompting pharma to adopt new business models
New partnerships were announced, and sessions highlighted new vaccines, cutting-edge immune-inflammation drugs, and advances in cell and gene therapies. But there was a palpable feeling of caution in the air.